journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://www.readbyqxmd.com/read/29349682/managing-obesity-in-primary-care-breaking-down-the-barriers
#1
REVIEW
Nicholas Forgione, Gary Deed, Gary Kilov, Georgia Rigas
Several Australian obesity management guidelines have been developed for general practice but, to date, implementation of these guidelines has been shown to be inadequate. In this review, we explore the barriers to obesity treatment and propose a four-stage plan to manage individuals with obesity in general practice using a framework of a multidisciplinary team. FUNDING: Novo Nordisk.
January 18, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29313286/once-daily-triple-therapy-in-patients-with-copd-patient-reported-symptoms-and-quality-of-life
#2
Maggie Tabberer, David A Lomas, Ruby Birk, Noushin Brealey, Chang-Qing Zhu, Steve Pascoe, Nicholas Locantore, David A Lipson
INTRODUCTION: Directly recorded patient experience of symptoms and health-related quality of life (HRQoL) can complement lung function and exacerbation rate data in chronic obstructive pulmonary disease (COPD) clinical studies. The FULFIL study recorded daily symptoms and activity limitation together with additional patient-reported outcomes of dyspnea and HRQoL, as part of the prespecified analyses. FULFIL co-primary endpoint data have been previously reported. METHODS: FULFIL was a phase III, 24-week, randomized, double-blind, double-dummy, multicenter study comparing once-daily single inhaler triple therapy [fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)] 100 µg/62...
January 8, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29313285/treatment-dosing-patterns-and-clinical-outcomes-for-patients-with-type-2-diabetes-starting-or-switching-to-treatment-with-insulin-glargine-300-units-per-milliliter-in-a-real-world-setting-a-retrospective-observational-study
#3
Shaloo Gupta, Hongwei Wang, Neil Skolnik, Liyue Tong, Ryan M Liebert, Lulu K Lee, Peter Stella, Anna Cali, Ronald Preblick
INTRODUCTION: Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter (Gla-300) have not been studied in real-world clinical practice. This study evaluated differences in dosing and clinical outcomes before and after Gla-300 treatment initiation in patients with type 2 diabetes starting or switching to treatment with Gla-300 to assess whether the benefits observed in clinical trials translate into real-world settings...
January 8, 2018: Advances in Therapy
https://www.readbyqxmd.com/read/29285708/intragastric-balloon-treatment-for-obesity-fda-safety-updates
#4
LETTER
Chinara M Tate, Allan Geliebter
Over the past year, the FDA has issued two letters to healthcare providers alerting them to adverse events associated with ORBERA and ReShape intragastric balloons (IGBs), including several deaths. Both IGB devices were FDA-approved for use in the US in the summer of 2015. Although the adverse events cited in the two letters occurred following FDA approval, there was already evidence prior to FDA approval that the safety and efficacy of ReShape and ORBERA were highly questionable. Since January 1, 2006, ORBERA and Reshape IGB have been implicated in 33 deaths...
December 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29285707/an-emerging-treatment-alternative-for-anemia-in-chronic-kidney-disease-patients-a-review-of-daprodustat
#5
REVIEW
Kimberly A Becker, John J Jones
This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.
December 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29273859/the-effect-of-novel-glucose-monitoring-system-flash-glucose-monitoring-on-mental-well-being-and-treatment-satisfaction-in-japanese-people-with-diabetes
#6
Sumie Mitsuishi, Rimei Nishimura, Shin-Ichi Harashima, Tomoyuki Kawamura, Daisuke Tsujino, Keiko Koide, Akiko Nishimura, Kazunori Utsunomiya, Nobuya Inagaki, Yoshihito Atsumi
INTRODUCTION: FreeStyle Libre (Abbot Diabetes Care Ltd) has been launched as a novel glucose monitoring system called flash glucose monitoring (FGM) in Europe. Several reports are becoming available on its usefulness and safety. To date, however, reports from Asian countries have not been made available. In this study, we evaluated its usefulness in Japanese people with diabetes in terms of its mental well-being and patient satisfaction outcomes. METHODS: Individuals with type 1 and 2 diabetes treated with insulin were enrolled, and they performed self-monitoring of blood glucose...
December 22, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29270781/long-term-effectiveness-of-liraglutide-for-treatment-of-type-2-diabetes-in-a-real-life-setting-a-24-month-multicenter-non-interventional-retrospective-study
#7
Annunziata Lapolla, Cesare Berra, Massimo Boemi, Antonio Carlo Bossi, Riccardo Candido, Graziano Di Cianni, Simona Frontoni, Stefano Genovese, Paola Ponzani, Vincenzo Provenzano, Giuseppina T Russo, Luigi Sciangula, Natalino Simioni, Cristiano Bette, Antonio Nicolucci
INTRODUCTION: The aim of the study was to evaluate whether the reduction in glycated hemoglobin (HbA1c) observed in clinical trials with liraglutide in type 2 diabetes (T2D) could be attained in routine clinical practice. METHODS: ReaL was a multicenter, non-interventional, observational, retrospective, longitudinal study on the effectiveness of liraglutide, a human glucagon-like peptide-1 analog, in individuals with T2D treated in daily practice in Italy. Between 26 March and 16 November 2015, data were taken from clinical records of patients aged ≥ 18 years with treatment follow-up data of up to 24 months and who received their first prescription of liraglutide in 2011...
December 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29270780/development-of-a-framework-based-on-reflective-mcda-to-support-patient-clinician-shared-decision-making-the-case-of-the-management-of-gastroenteropancreatic-neuroendocrine-tumors-gep-net-in-the-united-states
#8
Monika Wagner, Dima Samaha, Hanane Khoury, William M O'Neil, Louis Lavoie, Liga Bennetts, Danielle Badgley, Sylvie Gabriel, Anthony Berthon, James Dolan, Matthew H Kulke, Mireille Goetghebeur
INTRODUCTION: Well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are often slow-growing, and some patients with unresectable, asymptomatic, non-functioning tumors may face the choice between watchful waiting (WW), or somatostatin analogues (SSA) to delay progression. We developed a comprehensive multi-criteria decision analysis (MCDA) framework to help patients and physicians clarify their values and preferences, consider each decision criterion, and support communication and shared decision-making...
December 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29270779/review-of-post-marketing-safety-data-on-tapentadol-a-centrally-acting-analgesic
#9
REVIEW
Ariane Stollenwerk, Melanie Sohns, Fabian Heisig, Christian Elling, Detlef von Zabern
INTRODUCTION: Tapentadol is a centrally acting analgesic that has been available for the management of acute and chronic pain in routine clinical practice since 2009. METHODS: This is the first integrated descriptive analysis of post-marketing safety data following the use of tapentadol in a broad range of pain conditions relating to the topics overall safety, dose administration above approved dosages, administration during pregnancy, serotonin syndrome, respiratory depression, and convulsion...
December 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29222626/the-effect-of-phacoemulsification-on-intraocular-pressure-in-eyes-with-hyperfiltration-following-trabeculectomy-a-prospective-study
#10
Ivano Riva, Andreas Katsanos, Francesco Oddone, Luciano Quaranta
INTRODUCTION: The aim of this study was to evaluate the effect of visually non-significant cataract extraction in patients with hypotony maculopathy and reduced visual acuity due to over-filtering blebs after trabeculectomy. METHODS: Patients with intraocular pressure (IOP) < 6 mmHg and documented hypotony maculopathy due to over-filtering blebs after trabeculectomy were prospectively recruited. Eligible patients underwent visually non-significant cataract phacoemulsification, no earlier than 12 weeks from the diagnosis of hypotony maculopathy...
December 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29222625/using-patient-feedback-to-optimize-the-design-of-a-certolizumab-pegol-electromechanical-self-injection-device-insights-from-human-factors-studies
#11
Barbara Domańska, Oliver Stumpp, Steven Poon, Serkan Oray, Irina Mountian, Clovis Pichon
INTRODUCTION: We incorporated patient feedback from human factors studies (HFS) in the patient-centric design and validation of ava®, an electromechanical device (e-Device) for self-injecting the anti-tumor necrosis factor certolizumab pegol (CZP). METHODS: Healthcare professionals, caregivers, healthy volunteers, and patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or Crohn's disease participated in 11 formative HFS to optimize the e-Device design through intended user feedback; nine studies involved simulated injections...
December 8, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29209994/the-role-of-trypsin-chymotrypsin-in-tissue-repair
#12
REVIEW
Dilip Shah, Kushal Mital
Tissue damage of all types, such as surgical or accidental injuries, fractures, and burns, stimulates a well-orchestrated, physiological process of healing, which ultimately leads to structural and functional restoration of the damaged tissues. The tissue repair process can be broadly divided into four continuous and overlapping phases-hemostasis and coagulation, inflammation, proliferation, and remodeling. If the process is interrupted or halted during any stage, it leads to impaired healing and formation of a chronic wound...
December 5, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29185199/predictors-for-the-treatment-effect-of-sodium-glucose-co-transporter-2-inhibitors-in-patients-with-type-2-diabetes-mellitus
#13
Shusuke Yagi, Ken-Ichi Aihara, Takeshi Kondo, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Daiju Fukuda, Yutaka Nakaya, Kin-Ichiro Suwaki, Takashi Takeji, Toshihiro Wada, Hotimah Masdan Salim, Saori Hama, Tomomi Matsuura, Takayuki Ise, Kenya Kusunose, Koji Yamaguchi, Takeshi Tobiume, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Munehide Matsuhisa, Michio Shimabukuro, Masashi Akaike, Masataka Sata
INTRODUCTION: Predictors for the effect of sodium glucose co-transporter 2 (SGLT2) inhibitors at lowering hemoglobin A1c (HbA1c) levels in type 2 diabetes mellitus patients remain unclear. We therefore aimed to elucidate these predictors in type 2 diabetes patients after 3 months of SGLT2 treatment. METHODS: A total of 302 consecutive type 2 diabetes patients who had been treated with SGLT2 inhibitors as monotherapy or add-on therapy to existing antidiabetic treatments were enrolled retrospectively...
November 28, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29164480/dispensing-patterns-of-ranibizumab-and-aflibercept-for-the-treatment-of-neovascular-age-related-macular-degeneration-a-retrospective-cohort-study-in-australia
#14
Adrian Skelly, Hans-Joachim Carius, Vladimir Bezlyak, Fred K Chen
INTRODUCTION: Anti-vascular endothelial growth factor therapy is the standard of care for neovascular age-related macular degeneration (nAMD). The dosage of two licensed agents, ranibizumab and aflibercept, was established through clinical trials; however, it is unclear if either agent is administered as recommended in routine clinical practice. Using pharmacy claims data, we investigated if the dispensing patterns of ranibizumab differ from those of aflibercept 6 and 12 months after treatment initiation...
November 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29143928/systematic-literature-review-of-the-impact-of-endocrine-monotherapy-and-in-combination-with-targeted-therapy-on-quality-of-life-of-postmenopausal-women-with-hr-her2-advanced-breast-cancer
#15
REVIEW
Zhou Zhou, Derek H Tang, Jipan Xie, Rajeev Ayyagari, Eric Wu, Polly A Niravath
INTRODUCTION: A major treatment goal for advanced breast cancer (ABC) is to maintain or ideally improve patient quality of life (QoL). Given the changing disease landscape, this systematic literature review (SLR) aims to assess the impact of endocrine therapies (ET), including ET monotherapy (ET mono) and ET combined with targeted therapy (ET + TT), on QoL of women with HR+/HER2- ABC. METHODS: A SLR was conducted to identify randomized controlled trials (RCTs) meeting the following criteria: (1) included ET mono or ET + TT, (2) reported QoL outcomes, (3) focused on women with HR+/HER2- ABC, and (4) published after 2007 (when standardized HER2 testing became available)...
November 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29143926/prolonging-time-to-flare-in-pediatric-atopic-dermatitis-a-randomized-investigator-blinded-controlled-multicenter-clinical-study-of-a-ceramide-containing-moisturizer
#16
Lin Ma, Ping Li, Jianping Tang, Yifeng Guo, Chunping Shen, Jing Chang, Nabil Kerrouche
INTRODUCTION: Delaying or preventing flares is important in atopic dermatitis (AD) management. The objective of the study was to evaluate whether using a ceramide-containing moisturizer in addition to a body wash during latent AD can delay flares. METHODS: This was a randomized, investigator-blinded, parallel-group, controlled study among Chinese children with a history of mild to moderate AD, within 1 week of successful treatment with a topical corticosteroid...
November 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29134428/the-influence-of-hepatic-and-renal-impairment-on-the-pharmacokinetics-of-a-treatment-for-herpes-zoster-amenamevir-asp2151-phase-1-open-label-single-dose-parallel-group-studies
#17
Tomohiro Kusawake, Donna Kowalski, Akitsugu Takada, Kota Kato, Masataka Katashima, James J Keirns, Michaelene Lewand, Kenneth C Lasseter, Thomas C Marbury, Richard A Preston
INTRODUCTION: Amenamevir (ASP2151) is a nonnucleoside human herpesvirus helicase-primase inhibitor that was approved in Japan for the treatment of herpes zoster (shingles) in 2017. This article reports the results of two clinical trials that investigated the effects of renal and hepatic impairment on the pharmacokinetics of amenamevir. METHODS: These studies were phase 1, open-label, single-dose (oral 400 mg), parallel-group studies evaluating the pharmacokinetics, safety, and tolerability of amenamevir in healthy participants and participants with moderate hepatic impairment and mild, moderate, and severe renal impairment...
November 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29134427/overall-survival-of-patients-with-locally-advanced-or-metastatic-esophageal-squamous-cell-carcinoma-treated-with-nimotuzumab-in-the-real-world
#18
Yaimarelis Saumell, Lizet Sanchez, Sandra González, Ramón Ortiz, Edadny Medina, Yaima Galán, Agustin Lage
INTRODUCTION: Despite improvements in surgical techniques and treatments introduced into clinical practice, the overall survival of patients with esophageal squamous cell carcinoma remains low. Several epidermal growth factor receptor inhibitors are being evaluated in the context of clinical trials, but there is little evidence of effectiveness in real-world conditions. This study aimed at assessing the effectiveness of nimotuzumab combined with onco-specific treatment in Cuban real-life patients with locally advanced or metastatic esophageal squamous cell carcinoma...
November 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29134426/pharmacokinetics-and-safety-of-amenamevir-in-healthy-subjects-analysis-of-four-randomized-phase-1-studies
#19
Tomohiro Kusawake, James J Keirns, Donna Kowalski, Martin den Adel, Dorien Groenendaal-van de Meent, Akitsugu Takada, Yoshiaki Ohtsu, Masataka Katashima
INTRODUCTION: Amenamevir (ASP2151) is a nonnucleoside antiherpesvirus compound available for the treatment of varicella-zoster virus infections. In this article we summarize the findings of four phase 1 studies in healthy participants. METHODS: Four randomized phase 1 studies investigated the safety and pharmacokinetics of single and multiple doses of amenamevir, including the assessment of age group effect (nonelderly vs elderly), food effect, and the relative bioavailability of two formulations...
November 13, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29119403/evaluation-of-the-efficiency-of-single-inhaler-combination-therapy-with-budesonide-formoterol-fumarate-in-patients-with-bronchial-asthma-in-daily-clinical-practice
#20
Michał Pirożyński, Piotr Hantulik, Agnieszka Almgren-Rachtan, Jerzy Chudek
INTRODUCTION: The effectiveness of single-inhaler budesonide/formoterol fumarate combination therapy for asthma has been previously shown for the original product. The aim of this nonrandomized, open-label, postauthorization efficacy study (PAES) real-life clinical assessment was to evaluate the clinical effectiveness of a second product (Bufomix Easyhaler(®)) in the daily clinical practice of asthma therapy. METHODS: This multicenter PAES was conducted by 220 unselected allergologists and pulmonologists who enrolled 2200 adult outpatients (age 49...
November 8, 2017: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"